Back to Journals » Journal of Pain Research » Volume 17
Efficacy of Acupuncture-Related Therapy for Migraine: A Systematic Review and Network Meta-Analysis [Letter]
Received 9 December 2024
Accepted for publication 18 December 2024
Published 21 December 2024 Volume 2024:17 Pages 4449—4451
DOI https://doi.org/10.2147/JPR.S511184
Checked for plagiarism Yes
Editor who approved publication: Dr Houman Danesh
Guimei Guo,* Wensi Ouyang*
Changchun University of Chinese Medicine, Changchun, 130117, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wensi Ouyang, Changchun University of Chinese Medicine, Changchun, Jilin Province, 130117, People’s Republic of China, Tel +86-19958706928, Email [email protected]
View the original paper by Ms Liu and colleagues
Dear editor
We are interested in the article entitled “Efficacy of Acupuncture-Related Therapy for Migraine: A Systematic Review and Network Meta-Analysis”.1 The study provides a comprehensive analysis of the efficacy of various acupuncture-related therapies in the treatment of migraine. However, the article has raised some attention on our part. We would like to pose some pertinent, worthwhile questions to the investigators.
Firstly, conducting a comprehensive literature search is an essential prerequisite for ensuring the reliability of a meta-analysis. The authors1 reported in the results section an initial screening of 2981 potentially relevant studies. Figure 1 indicates a discrepancy in the reported number of studies identified through database searches. The total should be 3036 (90+794+681+582+314+141+133+50+251), rather than the stated 2981, highlighting a clear error in the data. Additionally, Figure 1 indicates that that after the authors read the titles and abstracts of 1867 articles, they excluded 1503 articles and should have obtained 364 articles after screening. It is worth noting that author screening resulted in only 337 relevant articles.1 The error in Figure 1 from Liu et al has been outlined with a red box in Figure 1. Therefore, further verification by the authors is required.
![]() |
Figure 1 The PRISMA flowchart from the study conducted by Liu et al.1 We indicated the data with errors using a red box. |
Finally, the specific acupoints are the most valuable information for acupuncture therapy treatment of migraine. Confusingly, the authors did not provide detailed acupuncture parameters such as insertion depth, needle retention time, and needle frequency. In addition, we have a small suggestion that the names of the acupuncture points be able to follow the standards of the World Health Organisation.2 For example Hegu (LI4), Fengchi (GB20), Zusanli (ST36), and Kunlun (BL60).
In conclusion, we express our sincere appreciation to Liu et al for their collaborative efforts in investigating the efficacy and safety of acupuncture in patients with migraine. They have made significant strides in this clinically relevant field. However, we would like to raise some questions that may contribute to enhancing the rigor and reliability of their research findings.
Disclosure
The authors declare no conflicts of interest in this communication.
References
1. Liu Y, Wang Y, Mi C, et al. Efficacy of acupuncture-related therapy for migraine: a systematic review and network meta-analysis. J Pain Res. 2024;17:1107–1132. doi:10.2147/JPR.S452971
2. Qiu T, Li L. Discussion on the Chinese edition of the WHO standard acupuncture point locations in the western pacific region. Zhongguo Zhenjiu. 2011;31(9):827–830. PMID: 21972638.
© 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.